bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's reven... bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates. Show more
- 74 patient starts completed or scheduled to date in 2024 across bluebird’s commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.038701 | 12.3527365233 | 0.313299 | 0.41 | 0.29 | 6576700 | 0.33708476 | CS |
4 | -0.1355 | -27.7948717949 | 0.4875 | 0.51 | 0.29 | 6104798 | 0.38623692 | CS |
12 | -0.1979 | -35.9883615203 | 0.5499 | 0.63 | 0.29 | 6130643 | 0.47328272 | CS |
26 | -0.638 | -64.4444444444 | 0.99 | 1.43 | 0.29 | 6560348 | 0.71204902 | CS |
52 | -3.648 | -91.2 | 4 | 5.53 | 0.29 | 8457783 | 1.25149769 | CS |
156 | -10.248 | -96.679245283 | 10.6 | 11.7 | 0.29 | 5846697 | 3.22996667 | CS |
260 | -77.618 | -99.5485443119 | 77.97 | 99.36 | 0.29 | 4013087 | 8.58098184 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales